GLP-1 drug cardiovascular benefits: tirzepatide study

What happened in GLP-1 drug cardiovascular benefits news

A study published by The BMJ reports that adding tirzepatide to standard care for people with type 2 diabetes and established heart disease was associated with a lower risk of major cardiovascular events over one year.

The researchers compared outcomes for people who started tirzepatide with those who started sitagliptin, which they selected as a “neutral placebo proxy” based on studies showing no cardiovascular effect.

A linked editorial said the estimate is useful for routine-care decision-making, but it does not establish a mortality indication or define the best sequencing of cardiometabolic therapy.

• Primary source: The BMJ study summarized in “the source” (Aug 5, 2026).
• Drug named in the report: tirzepatide (marketed as Mounjaro).
• Comparator: sitagliptin, chosen to approximate a neutral cardiovascular effect.

What the evidence shows about GLP-1 drug cardiovascular benefits

This evidence comes from an observational analysis of clinical practice data from two U.S. health insurance claims databases covering May 2022 to May 2025, not a randomized trial.

The analysis included 52,971 people (average age 70; 51% female) with type 2 diabetes, BMI at least 25, and established heart disease; 35,353 started tirzepatide and 17,618 started sitagliptin.

At one year, major adverse cardiovascular events (MACE: heart attack, stroke, and death from any cause) occurred in 2.9% of the tirzepatide group vs 4.4% of the sitagliptin group, described as a 32% relative reduction, and the researchers estimated one MACE prevented for every 70 patients who started tirzepatide.

• MACE at 1 year: 2.9% (tirzepatide) vs 4.4% (sitagliptin).
• Estimated prevention: 1 MACE per 70 patients starting tirzepatide.
• Components: 33% lower risk of heart attack; ischemic stroke showed no meaningful difference.

Other outcomes reported alongside GLP-1 drug cardiovascular benefits

Beyond cardiovascular events, the study also reported lower infection-related outcomes among people who started tirzepatide compared with sitagliptin during the one-year monitoring window.

Infections requiring hospital admission were lower, with an estimate of one admission prevented for every 48 patients starting tirzepatide.

The report also notes lower infection-related death, lower death from any cause, and provides estimated numbers needed to treat for each outcome.

• Infection-related hospitalization: 1 admission prevented per 48 patients starting tirzepatide.
• Infection-related death: 1 death prevented per 200 patients.
• Death from any cause: 1 death prevented per 122 patients.

Practical context for metabolic health decisions

For people managing type 2 diabetes plus known cardiovascular disease, this study suggests that initiating tirzepatide in routine care settings may be linked to fewer major cardiovascular events than initiating sitagliptin over one year.

The study tracked outcomes from the first day of treatment up to one year, or until a person stopped or switched treatment or left their health plan, and it adjusted for factors such as age, sex, race, BMI, prior heart problems, other chronic conditions, and medication use.

The linked editorial emphasizes that population-level cardiovascular benefit depends on sustained access and persistence, and it flags real-world barriers such as cost, authorization hurdles, supply, and discontinuation that can limit impact.

• Applies to: type 2 diabetes + BMI ≥25 + established heart disease (as analyzed in claims data).
• Timeframe: monitored up to 1 year from treatment start (with stop/switch/disenrollment ending follow-up).
• Real-world barrier highlighted: access and long-term continuation may limit benefit.

Limitations and caveats for GLP-1 drug cardiovascular benefits claims

Because this was an observational study using insurance claims, it can show associations but cannot fully prove cause and effect the way a randomized trial can.

The researchers said they previously benchmarked their design, data, and analytics infrastructure against a randomized controlled trial before drawing conclusions, but they still note important limitations.

They highlighted a relatively short follow-up that may underestimate long-term cardiovascular and safety effects, possible misclassification of treatment duration or outcomes, and limited generalizability beyond people with established cardiovascular disease or beyond other health systems.

• Study type: observational claims analysis, not a randomized trial.
• Short follow-up: may miss longer-term benefits or risks.
• Generalizability: may not apply to patients without established cardiovascular disease.